Your browser doesn't support javascript.
loading
The effect of ciprofloxacin prophylaxis during haematopoietic cell transplantation on infection episodes, exposure to treatment antimicrobials and antimicrobial resistance: a single-centre retrospective cohort study.
Baltas, Ioannis; Kavallieros, Konstantinos; Konstantinou, Giannis; Koutoumanou, Eirini; Gibani, Malick M; Gilchrist, Mark; Davies, Frances; Pavlu, Jiri.
Afiliação
  • Baltas I; Department of Infection, Immunity and Inflammation, Institute of Child Health, University College London, London, UK.
  • Kavallieros K; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Konstantinou G; Faculty of Medicine, Imperial College London, London, UK.
  • Koutoumanou E; Faculty of Medicine, Imperial College London, London, UK.
  • Gibani MM; Population, Policy & Practice Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London, London, UK.
  • Gilchrist M; Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.
  • Davies F; Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.
  • Pavlu J; Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.
JAC Antimicrob Resist ; 6(1): dlae010, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38304723
ABSTRACT

Objectives:

Fluroquinolone prophylaxis during haematopoietic cell transplantation (HCT) remains contentious. We aimed to determine its effectiveness and association with exposure to treatment antimicrobials and antimicrobial resistance.

Methods:

All admission episodes for HCT (N = 400 , 372 unique patients) in a tertiary centre between January 2020 and December 2022 were studied. Allogeneic HCT (allo-HCT) recipients received prophylaxis with ciprofloxacin during chemotherapy-induced neutropenia, while autologous HCT (auto-HCT) recipients did not.

Results:

Allo-HCT was performed for 43.3% (173/400) of patients, auto-HCT for 56.7% (227/400). Allo-HCT was associated with an average of 1.01 fewer infection episodes per 100 admission days (95% CI 0.62-1.40, P < 0.001) compared with auto-HCT. In allo-HCT, the total exposure to all antimicrobials was higher [+24.8 days of therapy (DOT)/100 admission days, P < 0.001], as was exposure to ciprofloxacin (+40.5 DOT/100 admission days, P < 0.001). By contrast, exposure to meropenem (-4.5 DOT/100 admission days, P = 0.02), piperacillin/tazobactam (-5.2 DOT/100 admission days, P < 0.001), aminoglycosides (-4.5 DOT/100 admission days, P < 0.001) and glycopeptides (-6.4 DOT/100 admission days, P < 0.001) was reduced. Enterobacteriaceae isolated during allo-HCT were more resistant to ciprofloxacin (65.5%, 19/29 versus 6.1%, 2/33, P < 0001), ceftriaxone (65.5%, 19/29 versus 9.1%, 3/33, P < 0.001), other antimicrobial classes. Vancomycin-resistant enterococci were more common in allo-HCT recipients (11%, 19/173 versus 0.9%, 2/227, P < 0.001). Inpatient mortality during allo- and auto-HCT was 9.8% (17/173) and 0.4% (1/227). respectively (P < 0.001).

Conclusions:

Ciprofloxacin prophylaxis in allo-HCT was associated with fewer infection episodes and reduced exposure to treatment antimicrobials. Mortality in auto-HCT remained low. A significant burden of antimicrobial resistance was detected in allo-HCT recipients.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2024 Tipo de documento: Article